EVH

SEC source: 0001232583-17-000007 · primary_doc.xml · nonDerivative · entry 1

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,411

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.

F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001359252-17-000001 · primary_doc.xml · nonDerivative · entry 1

SAMET KENNETH A · CIK 0001359252 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,850

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001232583-17-000006 · primary_doc.xml · derivative · entry 4

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,680

Underlying: Class A Common Stock · 6,000 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on October 1, 2014.

SEC source: 0001232583-17-000006 · primary_doc.xml · nonDerivative · entry 3

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,370

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.

F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001232583-17-000006 · primary_doc.xml · nonDerivative · entry 2

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,770

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.

F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $23.00-$23.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001232583-17-000006 · primary_doc.xml · nonDerivative · entry 1

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016.

F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001204938-17-000005 · primary_doc.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 834,183

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016.

F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001204938-17-000005 · primary_doc.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 845,983

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016.

F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.90-$23.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001654824-17-000001 · primary_doc.xml · derivative · entry 7

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,722

Underlying: Class A Common Stock · 2,908 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2017.

SEC source: 0001654824-17-000001 · primary_doc.xml · derivative · entry 6

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Class A Common Stock · 1,000 shares

Expires 2025-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Class A Common Stock Options exercised vested on January 1, 2017.

SEC source: 0001654824-17-000001 · primary_doc.xml · nonDerivative · entry 5

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,587

F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.75-23.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote.

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001654824-17-000001 · primary_doc.xml · nonDerivative · entry 4

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001654824-17-000001 · primary_doc.xml · nonDerivative · entry 3

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,587

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001654824-17-000001 · primary_doc.xml · nonDerivative · entry 2

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001654824-17-000001 · primary_doc.xml · nonDerivative · entry 1

Stone Lydia · CIK 0001654824 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,587

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001643346-17-000010 · primary_doc.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,205

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.60-$23.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of the Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001644244-17-000003 · primary_doc.xml · nonDerivative · entry 1

UPMC · CIK 0001644244 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,434,283

SEC source: 0000903423-17-000376 · tpgrowthadii4evolent.xml · derivative · entry 3

TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8)

BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8)

COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 4,279,501

Underlying: Class A Common Stock · 2,606,609 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: TPG Eagle Holdings, L.P. ("TPG Eagle") holds an aggregate of 4,279,501 Class B Common Units (the "Class B Units") of Evolent Health LLC and 4,279,501 shares of Class B Common Stock (the "Class B Shares") of Evolent Health, Inc. (the "Issuer").

F2 · security: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F3 · security: On May 19, 2017, TPG Eagle exchanged 2,606,609 Class B Units (along with 2,606,609 Class B Shares) for Class A Shares on a one-for-one basis.

F2 · derivative.exercise_price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F3 · derivative.exercise_price: On May 19, 2017, TPG Eagle exchanged 2,606,609 Class B Units (along with 2,606,609 Class B Shares) for Class A Shares on a one-for-one basis.

F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F3 · price: On May 19, 2017, TPG Eagle exchanged 2,606,609 Class B Units (along with 2,606,609 Class B Shares) for Class A Shares on a one-for-one basis.

F2 · derivative.exercise_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F2 · derivative.expiration_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F1 · ownership.nature: TPG Eagle Holdings, L.P. ("TPG Eagle") holds an aggregate of 4,279,501 Class B Common Units (the "Class B Units") of Evolent Health LLC and 4,279,501 shares of Class B Common Stock (the "Class B Shares") of Evolent Health, Inc. (the "Issuer").

F2 · ownership.nature: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds.

F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any.

F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders.

F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0000903423-17-000376 · tpgrowthadii4evolent.xml · nonDerivative · entry 2

TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8)

BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8)

COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 780,098

F4 · ownership.nature: TPG Growth II BDH, L.P. ("Growth II BDH" and, together with TPG Eagle, the "TPG Funds") holds an aggregate of 780,098 Class A Shares.

F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds.

F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any.

F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders.

F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0000903423-17-000376 · tpgrowthadii4evolent.xml · nonDerivative · entry 1

TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8)

BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8)

COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 3,861,858

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date.

F3 · price: On May 19, 2017, TPG Eagle exchanged 2,606,609 Class B Units (along with 2,606,609 Class B Shares) for Class A Shares on a one-for-one basis.

F4 · ownership.nature: TPG Growth II BDH, L.P. ("Growth II BDH" and, together with TPG Eagle, the "TPG Funds") holds an aggregate of 780,098 Class A Shares.

F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds.

F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any.

F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders.

F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

SEC source: 0001209191-17-034687 · doc4.xml · derivative · entry 3

ADVISORY BOARD CO · CIK 0001157377 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,772,898

Underlying: Class A Common Stock · 1,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc (the "Issuer"), Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), The Advisory Board Company has exchanged a portion of its Class B Units (along with a corresponding number of its Class B Common Stock, or the "Class B Shares" of the Issuer) for Class A Common Stock (the "Class A Shares" of the Issuer) on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members.

F1 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc (the "Issuer"), Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), The Advisory Board Company has exchanged a portion of its Class B Units (along with a corresponding number of its Class B Common Stock, or the "Class B Shares" of the Issuer) for Class A Common Stock (the "Class A Shares" of the Issuer) on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members.

F2 · price: On May 19, 2017, The Advisory Board Company exchanged 1,000,000 Class B Units (along with 1,000,000 Class B Shares) for 1,000,000 Class A Shares.

F1 · derivative.exercise_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc (the "Issuer"), Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), The Advisory Board Company has exchanged a portion of its Class B Units (along with a corresponding number of its Class B Common Stock, or the "Class B Shares" of the Issuer) for Class A Common Stock (the "Class A Shares" of the Issuer) on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members.

F4 · derivative.exercise_date: The Advisory Board Company holds an aggregate of 1,772,898 Class B Units of Evolent Health, LLC and 1,772,898 shares of Class B Shares of the Issuer.

F1 · derivative.expiration_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc (the "Issuer"), Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), The Advisory Board Company has exchanged a portion of its Class B Units (along with a corresponding number of its Class B Common Stock, or the "Class B Shares" of the Issuer) for Class A Common Stock (the "Class A Shares" of the Issuer) on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members.

F4 · derivative.expiration_date: The Advisory Board Company holds an aggregate of 1,772,898 Class B Units of Evolent Health, LLC and 1,772,898 shares of Class B Shares of the Issuer.

SEC source: 0001209191-17-034687 · doc4.xml · nonDerivative · entry 2

ADVISORY BOARD CO · CIK 0001157377 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,128,167

F3 · price: The price represents the public offering price of $24.65 per share of Class A Shares of the Issuer less the underwriters' discount of $0.35 per Class A Share.

SEC source: 0001209191-17-034687 · doc4.xml · nonDerivative · entry 1

ADVISORY BOARD CO · CIK 0001157377 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,128,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc (the "Issuer"), Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), The Advisory Board Company has exchanged a portion of its Class B Units (along with a corresponding number of its Class B Common Stock, or the "Class B Shares" of the Issuer) for Class A Common Stock (the "Class A Shares" of the Issuer) on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members.

F2 · price: On May 19, 2017, The Advisory Board Company exchanged 1,000,000 Class B Units (along with 1,000,000 Class B Shares) for 1,000,000 Class A Shares.

SEC source: 0000950157-17-000718 · form4.xml · derivative · entry 3

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,431

Underlying: Class A Common Stock · 17,230 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2015.

SEC source: 0000950157-17-000718 · form4.xml · nonDerivative · entry 2

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,022

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000718 · form4.xml · nonDerivative · entry 1

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,252

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000719 · form4.xml · derivative · entry 3

McGrane Nicholas · CIK 0001643086 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,952

Underlying: Class A Common Stock · 47,508 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Class A Common Stock Options exercised vested on November 1, 2015.

SEC source: 0000950157-17-000719 · form4.xml · nonDerivative · entry 2

McGrane Nicholas · CIK 0001643086 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,084

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000719 · form4.xml · nonDerivative · entry 1

McGrane Nicholas · CIK 0001643086 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000723 · form4.xml · nonDerivative · entry 1

WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,370

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000720 · form4.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850,483

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000722 · form4.xml · nonDerivative · entry 1

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,285

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0000950157-17-000721 · form4.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432,205

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001656979-17-000001 · primary_doc.xml · nonDerivative · entry 1

Scott Cheryl · CIK 0001656979 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,373

F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 4

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,761

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017.

F5 · price: The price reported in Column4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.85-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 3

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,538

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017.

F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.85-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 2

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,315

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017.

F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.90-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 1

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,092

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017.

F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.90-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643346-17-000009 · primary_doc.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 760,944

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F2 · price: The price reported in Column4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.90-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000002 · primary_doc.xml · derivative · entry 4

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,307

Underlying: Class A Common Stock · 9,328 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F3 · derivative.exercise_date: The Class A Common Stock Options exercised began vesting at a rate of 25% annually beginning December 1, 2014.

SEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 3

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,869

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 2

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,983

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

SEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 1

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,311

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

SEC source: 0001643086-17-000003 · primary_doc.xml · derivative · entry 3

McGrane Nicholas · CIK 0001643086 · Cheif Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,460

Underlying: Class A Common Stock · 1,667 shares

Expires 2024-10-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016.

F3 · derivative.exercise_date: The Class A Common Stock exercised vested on November 1, 2015. One fourth of the Class A Common Stock Options granted to the reporting person on October 22, 2014 vested on November 1, 2015; the balance vested or vests at a rate of 6.25% as of the end of each three-month period immediately thereafter during the period beginning on October 23, 2015, the day following the first anniversary of the grant date.

SEC source: 0001643086-17-000003 · primary_doc.xml · nonDerivative · entry 2

McGrane Nicholas · CIK 0001643086 · Cheif Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,380

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016.

F2 · price: The shares were sold in multiple transactions at prices ranging from $23.90-$24.65, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643086-17-000003 · primary_doc.xml · nonDerivative · entry 1

McGrane Nicholas · CIK 0001643086 · Cheif Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016.

SEC source: 0001643498-17-000001 · primary_doc.xml · derivative · entry 4

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,635

Underlying: Class A Common Stock · 6,265 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F4 · derivative.exercise_date: The Class A Common Stock Options exercised began vesting at a rate of 25% annually beginning December 15, 2014.

SEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 3

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,983

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 2

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,322

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.

F2 · price: The price reported in Column 4 is a weighted average. These shares sold in multiple transactions at prices ranging from $25.00-$25.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 1

Peterson Thomas III · CIK 0001643498 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 395,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016.